• Je něco špatně v tomto záznamu ?

Effect of prasugrel pre-treatment strategy in patients undergoing percutaneous coronary intervention for NSTEMI: the ACCOAST-PCI study

G. Montalescot, JP. Collet, P. Ecollan, L. Bolognese, J. Ten Berg, D. Dudek, C. Hamm, P. Widimsky, JF. Tanguay, P. Goldstein, E. Brown, DL. Miller, L. LeNarz, E. Vicaut, . ,

. 2014 ; 64 (24) : 2563-71.

Jazyk angličtina Země Spojené státy americké

Typ dokumentu časopisecké články, multicentrická studie, randomizované kontrolované studie, práce podpořená grantem

Perzistentní odkaz   https://www.medvik.cz/link/bmc15013959

BACKGROUND: After percutaneous coronary intervention (PCI) for non-ST-segment elevation myocardial infarction (NSTEMI), treatment with a P2Y12 antagonist with aspirin is recommended for 1 year. OBJECTIVES: The oral P2Y12 antagonists ticagrelor and prasugrel have higher recommendations than clopidogrel, but it is unknown if administration before the start of PCI is beneficial. METHODS: In the randomized, double-blind ACCOAST (A Comparison of prasugrel at the time of percutaneous Coronary intervention Or as pre-treatment At the time of diagnosis in patients with non-ST-segment elevation myocardial infarction) trial, 4,033 patients were diagnosed with NSTEMI and 68.7% underwent PCI; 1,394 received pre-treatment with prasugrel (30-mg loading dose), and 1,376 received placebo. At the time of PCI, patients who received pre-treatment with prasugrel received an additional 30-mg dose of prasugrel, and those who received placebo received a 60-mg loading dose of prasugrel. Primary efficacy was a composite of cardiovascular death, myocardial infarction, stroke, urgent revascularization, or glycoprotein IIb/IIIa bailout through 7 days from randomization. Investigators captured the presence of thrombus on initial angiography and during PCI. RESULTS: The incidence of the primary endpoint through 7 days from randomization in the pre-treatment group versus the no pre-treatment group was 13.1% versus 13.1% (p = 0.93). Pre-treatment with prasugrel was not associated with decreases in any ischemic event, including total mortality. Patients with thrombus on angiography had a 3-fold higher incidence of the primary endpoint than patients without thrombus. There was no impact of pre-treatment with prasugrel on the presence of thrombus before PCI or on occurrence of stent thrombosis after PCI. There was a 3-fold increase in all non-coronary artery bypass graft Thrombolysis In Myocardial Infarction (TIMI) major bleeding and a 6-fold increase in non-coronary artery bypass graft life-threatening bleeding with pre-treatment with prasugrel; the same trends persisted in patients who had radial or femoral access even with use of a closure device. CONCLUSIONS: These findings support deferring treatment with prasugrel until a decision is made about revascularization in patients with NSTEMI undergoing angiography within 48 h of admission. (A Comparison of prasugrel at the time of percutaneous Coronary intervention Or as pre-treatment At the time of diagnosis in patients with non-ST-segment elevation myocardial infarction [ACCOAST]; NCT01015287).

Citace poskytuje Crossref.org

000      
00000naa a2200000 a 4500
001      
bmc15013959
003      
CZ-PrNML
005      
20150428103143.0
007      
ta
008      
150420s2014 xxu f 000 0|eng||
009      
AR
024    7_
$a 10.1016/j.jacc.2014.08.053 $2 doi
035    __
$a (PubMed)25524333
040    __
$a ABA008 $b cze $d ABA008 $e AACR2
041    0_
$a eng
044    __
$a xxu
100    1_
$a Montalescot, Gilles $u ACTION Study Group, Institut de Cardiologie, UPMC Université Paris 6, INSERM UMRS-1166 Paris, Centre Hospitalier Universitaire Pitié-Salpêtriėre (AP-HP), Paris, France. Electronic address: gilles.montalescot@psl.aphp.fr.
245    10
$a Effect of prasugrel pre-treatment strategy in patients undergoing percutaneous coronary intervention for NSTEMI: the ACCOAST-PCI study / $c G. Montalescot, JP. Collet, P. Ecollan, L. Bolognese, J. Ten Berg, D. Dudek, C. Hamm, P. Widimsky, JF. Tanguay, P. Goldstein, E. Brown, DL. Miller, L. LeNarz, E. Vicaut, . ,
520    9_
$a BACKGROUND: After percutaneous coronary intervention (PCI) for non-ST-segment elevation myocardial infarction (NSTEMI), treatment with a P2Y12 antagonist with aspirin is recommended for 1 year. OBJECTIVES: The oral P2Y12 antagonists ticagrelor and prasugrel have higher recommendations than clopidogrel, but it is unknown if administration before the start of PCI is beneficial. METHODS: In the randomized, double-blind ACCOAST (A Comparison of prasugrel at the time of percutaneous Coronary intervention Or as pre-treatment At the time of diagnosis in patients with non-ST-segment elevation myocardial infarction) trial, 4,033 patients were diagnosed with NSTEMI and 68.7% underwent PCI; 1,394 received pre-treatment with prasugrel (30-mg loading dose), and 1,376 received placebo. At the time of PCI, patients who received pre-treatment with prasugrel received an additional 30-mg dose of prasugrel, and those who received placebo received a 60-mg loading dose of prasugrel. Primary efficacy was a composite of cardiovascular death, myocardial infarction, stroke, urgent revascularization, or glycoprotein IIb/IIIa bailout through 7 days from randomization. Investigators captured the presence of thrombus on initial angiography and during PCI. RESULTS: The incidence of the primary endpoint through 7 days from randomization in the pre-treatment group versus the no pre-treatment group was 13.1% versus 13.1% (p = 0.93). Pre-treatment with prasugrel was not associated with decreases in any ischemic event, including total mortality. Patients with thrombus on angiography had a 3-fold higher incidence of the primary endpoint than patients without thrombus. There was no impact of pre-treatment with prasugrel on the presence of thrombus before PCI or on occurrence of stent thrombosis after PCI. There was a 3-fold increase in all non-coronary artery bypass graft Thrombolysis In Myocardial Infarction (TIMI) major bleeding and a 6-fold increase in non-coronary artery bypass graft life-threatening bleeding with pre-treatment with prasugrel; the same trends persisted in patients who had radial or femoral access even with use of a closure device. CONCLUSIONS: These findings support deferring treatment with prasugrel until a decision is made about revascularization in patients with NSTEMI undergoing angiography within 48 h of admission. (A Comparison of prasugrel at the time of percutaneous Coronary intervention Or as pre-treatment At the time of diagnosis in patients with non-ST-segment elevation myocardial infarction [ACCOAST]; NCT01015287).
650    _2
$a senioři $7 D000368
650    _2
$a angiografie $x metody $7 D000792
650    _2
$a vztah mezi dávkou a účinkem léčiva $7 D004305
650    _2
$a dvojitá slepá metoda $7 D004311
650    _2
$a elektrokardiografie $x metody $7 D004562
650    _2
$a stanovení cílového parametru $7 D023381
650    _2
$a ženské pohlaví $7 D005260
650    12
$a krvácení $x chemicky indukované $x prevence a kontrola $7 D006470
650    _2
$a lidé $7 D006801
650    12
$a peroperační komplikace $x chemicky indukované $x prevence a kontrola $7 D007431
650    _2
$a mužské pohlaví $7 D008297
650    _2
$a lidé středního věku $7 D008875
650    12
$a infarkt myokardu $x diagnóza $x terapie $7 D009203
650    12
$a koronární angioplastika $x škodlivé účinky $x metody $7 D062645
650    12
$a piperaziny $x aplikace a dávkování $x škodlivé účinky $7 D010879
650    _2
$a inhibitory agregace trombocytů $x aplikace a dávkování $x škodlivé účinky $7 D010975
650    _2
$a trombocytový glykoproteinový komplex IIb-IIIa $x analýza $7 D019039
650    _2
$a předoperační péče $x metody $7 D011300
650    _2
$a hodnocení rizik $7 D018570
650    12
$a thiofeny $x aplikace a dávkování $x škodlivé účinky $7 D013876
650    _2
$a výsledek terapie $7 D016896
655    _2
$a časopisecké články $7 D016428
655    _2
$a multicentrická studie $7 D016448
655    _2
$a randomizované kontrolované studie $7 D016449
655    _2
$a práce podpořená grantem $7 D013485
700    1_
$a Collet, Jean-Philippe $u ACTION Study Group, Institut de Cardiologie, UPMC Université Paris 6, INSERM UMRS-1166 Paris, Centre Hospitalier Universitaire Pitié-Salpêtriėre (AP-HP), Paris, France.
700    1_
$a Ecollan, Patrick $u ACTION Study Group, SMUR, Centre Hospitalier Universitaire Pitié-Salpêtriėre (AP-HP), Paris, France.
700    1_
$a Bolognese, Leonardo $u Cardiovascular and Neurological Department, Azienda Ospedaliera, Arezzo, Italy.
700    1_
$a Ten Berg, Jurrien $u Department of Cardiology, St. Antonius Hospital, Nieuwegein, the Netherlands.
700    1_
$a Dudek, Dariusz $u Institute of Cardiology, Jagiellonian University Medical College, University Hospital, Krakow, Poland.
700    1_
$a Hamm, Christian $u Kerckhoff Heart and Thoraxcenter, Bad Nauheim and Medical Clinic I, University of Giessen, Giessen, Germany.
700    1_
$a Widimsky, Petr $u Third Medical Faculty of Charles University and University Hospital Royal Vineyards, Prague, Czech Republic.
700    1_
$a Tanguay, Jean-François $u Montreal Heart Institute, Montreal, Quebec, Canada.
700    1_
$a Goldstein, Patrick $u SAMU and Emergency Department, Lille University Hospital, Lille, France.
700    1_
$a Brown, Eileen $u Eli Lilly and Company, Lilly Corporate Center, Indianapolis, Indiana.
700    1_
$a Miller, Debra L $u Eli Lilly and Company, Lilly Corporate Center, Indianapolis, Indiana.
700    1_
$a LeNarz, LeRoy $u Eli Lilly and Company, Lilly Corporate Center, Indianapolis, Indiana.
700    1_
$a Vicaut, Eric $u ACTION Study Group, Methodology and Statistical Unit, Centre Hospitalier Universitaire Lariboisière (AP-HP), Université Paris 7, Paris, France.
700    1_
$a ,
773    0_
$w MED00002964 $t Journal of the American College of Cardiology $x 1558-3597 $g Roč. 64, č. 24 (2014), s. 2563-71
856    41
$u https://pubmed.ncbi.nlm.nih.gov/25524333 $y Pubmed
910    __
$a ABA008 $b sig $c sign $y a $z 0
990    __
$a 20150420 $b ABA008
991    __
$a 20150428103446 $b ABA008
999    __
$a ok $b bmc $g 1071540 $s 896837
BAS    __
$a 3
BAS    __
$a PreBMC
BMC    __
$a 2014 $b 64 $c 24 $d 2563-71 $i 1558-3597 $m Journal of the American College of Cardiology $n J. Am. Coll. Cardiol. $x MED00002964
LZP    __
$a Pubmed-20150420

Najít záznam

Citační ukazatele

Možnosti archivace